Preanalytical stability of molecular forms of prostate‐specific antigen in serum samples (PSA, free PSA, [−2]proPSA) and their impact on fPSA/tPSA ratio and PHI

Abstract

AbstractBackgroundProstate cancer is a common cancer in men. Detection methods include the measurement of biomarkers: prostate‐specific antigen (PSA), free PSA, [−2]proPSA, and the calculated indices: fPSA/tPSA ratio and Prostate Health Index (PHI). Proper preanalytical conditions are crucial for precise measurement and failure to adhere to protocols or regulations can influence the diagnostic algorithm. We assessed the stability of the above‐mentioned biomarkers, fPSA/tPSA ratio and PHI, under various pre‐analytical conditions.MethodsSerum samples from 45 males were collected and stored under specific conditions before tPSA, fPSA, and [−2]proPSA were measured. Subsequently, the fPSA/tPSA and PHI were calculated.ResultstPSA, fPSA, and [−2]proPSA remained stable during the two freeze‐thaw cycles. Storage at 4°C and 22°C resulted in stable tPSA concentrations. However, fPSA levels decreased and [−2]proPSA levels increased over time. The fPSA/tPSA ratio remained stable for 72 h, at which point a decrease was observed in the samples kept at 4°C and 22°C. A gradual increase in PHI was observed in the samples kept at 4°C and 22°C.ConclusionsAll biomarkers remained stable during two freeze‐thaw cycles. tPSA was the most stable analyte when stored at 4°C, as well as at RT. A gradual increase of [−2]proPSA and a slight decrease in fPSA were observed during the storage test. This led to a decrease in the fPSA/tPSA ratio and an elevation in the PHI. We therefore recommend measuring prostate biomarkers promptly following blood collection.ImpactUnderstanding the pre‐analytical stability of prostate biomarkers helps prevent false positive results and improve the accuracy of diagnostics for prostate cancer.